Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Shaygannejad

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Neurologia|January 24, 2026
Association between comorbidities and health-related quality of life in patients with multiple sclerosisO Mirmosayyeb, M Barzegar, M Rezaei, et al.
European Journal of Neurology|March 27, 2015
BREMSO: a simple score to predict early the natural course of multiple sclerosisR Bergamaschi, C Montomoli, G Mallucci, et al.
Journal of Medical Economics|December 12, 2023
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United KingdomT Spelman, W L Herring, C Acosta, et al.
BMC Medical Research Methodology|May 31, 2022
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisM Lefort, S Sharmin, J B Andersen, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Neurologia|January 24, 2026
Association between comorbidities and health-related quality of life in patients with multiple sclerosisO Mirmosayyeb, M Barzegar, M Rezaei, et al.
European Journal of Neurology|March 27, 2015
BREMSO: a simple score to predict early the natural course of multiple sclerosisR Bergamaschi, C Montomoli, G Mallucci, et al.
Journal of Medical Economics|December 12, 2023
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United KingdomT Spelman, W L Herring, C Acosta, et al.
BMC Medical Research Methodology|May 31, 2022
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisM Lefort, S Sharmin, J B Andersen, et al.
Pageof 2